LNTH - Company ID 0001521036
Lantheus Holdings, Inc. trades as LNTH and has a market capitalization of $6.90 B, making it the #1178 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.54B, up 0.5% from the prior year and net income of $233.56M. This page tracks Lantheus Holdings, Inc. through 1,070 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Lantheus Holdings, Inc.'s revenue grew from $301.85M to $1.54B, a compound annual growth rate of 19.9%. Net profit margin compressed from 37.2% to 15.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com . A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.
Date & Time: Monday, June 1, 2026 , 10:30 am – 11:15 am PT
Title: A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted 177 lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.
Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026
To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.
The largest companies sharing Lantheus Holdings, Inc.'s SEC industry classification (in vitro & in vivo diagnostic substances).
Lantheus Holdings, Inc. (LNTH) has a market capitalization of $6.90 B as of 2026-07-09, ranking #1178 among US-listed companies.
Lantheus Holdings, Inc. reported revenue of $1.54B for fiscal year 2025, an increase of 0.5% year over year.
Yes. Lantheus Holdings, Inc. reported net income of $233.56M in its latest fiscal year.